Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0S3YP
|
||||
Former ID |
DIB018210
|
||||
Drug Name |
[3H](+)-isradipine
|
||||
Synonyms |
(+)-[3H]isradipine; (+)-[3H]O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 3H-(+)-PN 200-110
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C19H21N3O5
|
||||
InChI |
InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3/t16-/m0/s1
|
||||
InChIKey |
HMJIYCCIJYRONP-INIZCTEOSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Voltage-dependent L-type calcium channel alpha-1D subunit | Target Info | Inhibitor (gating inhibitor) | [2] | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Target Info | Inhibitor (gating inhibitor) | [3] | ||
Cav1.1 | Target Info | Inhibitor (gating inhibitor) | [4] | ||
KEGG Pathway | MAPK signaling pathway | ||||
Calcium signaling pathway | |||||
cGMP-PKG signaling pathway | |||||
cAMP signaling pathway | |||||
Cardiac muscle contraction | |||||
Adrenergic signaling in cardiomyocytes | |||||
Vascular smooth muscle contraction | |||||
Circadian entrainment | |||||
Retrograde endocannabinoid signaling | |||||
Glutamatergic synapse | |||||
Cholinergic synapse | |||||
Serotonergic synapse | |||||
GABAergic synapse | |||||
Dopaminergic synapse | |||||
Insulin secretion | |||||
GnRH signaling pathway | |||||
Oxytocin signaling pathway | |||||
Type II diabetes mellitus | |||||
Carbohydrate digestion and absorption | |||||
Alzheimer's disease | |||||
Amphetamine addiction | |||||
Hypertrophic cardiomyopathy (HCM) | |||||
Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
Dilated cardiomyopathyhsa04010:MAPK signaling pathway | |||||
Long-term potentiation | |||||
Dilated cardiomyopathy | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
Nicotinic acetylcholine receptor signaling pathway | |||||
5HT2 type receptor mediated signaling pathway | |||||
Beta1 adrenergic receptor signaling pathway | |||||
Beta2 adrenergic receptor signaling pathway | |||||
Oxytocin receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway | |||||
Oxytocin receptor mediated signaling pathway | |||||
Nicotine pharmacodynamics pathway | |||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | Adrenaline,noradrenaline inhibits insulin secretion | ||||
NCAM1 interactions | |||||
Regulation of insulin secretionR-HSA-400042:Adrenaline,noradrenaline inhibits insulin secretion | |||||
Regulation of insulin secretion | |||||
WikiPathways | Calcium Regulation in the Cardiac Cell | ||||
Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
Alzheimers Disease | |||||
NCAM signaling for neurite out-growth | |||||
Integration of energy metabolismWP536:Calcium Regulation in the Cardiac Cell | |||||
Integration of energy metabolism | |||||
Nicotine Activity on Chromaffin Cells | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2733). | ||||
REF 2 | Alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6. Epub 2001 Apr 2. | ||||
REF 3 | Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest. 2004 May;113(10):1430-9. | ||||
REF 4 | Biochemical characterization of plasma membrane isolated from human skeletal muscle. FEBS Lett. 1985 Sep 2;188(2):222-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.